Palvella Therapeutics granted FDA rolling review for QTORIN

• The FDA granted rolling review for Palvella Therapeutics' rare disease drug candidate.
• Following the regulatory announcement, the company's stock value climbed to 113.10 dollars.
• Management plans to complete its comprehensive marketing application by late 2026.

Palvella Therapeutics (NASDAQ:PVLA) announced that the FDA granted rolling review for its rare genetic disease drug application.

This rolling mechanism contrasts with standard review pathways that require full submission before initial agency evaluation begins.

"We remain on track to complete submission of the QTORIN rapamycin NDA in the second half of 2026," said Palvella Therapeutics Founder and Chief Executive Officer Wes Kaupinen.

The specialized treatment candidate previously secured Breakthrough Therapy, Fast Track, and Orphan Drug designations from regulators.

The underlying therapy addresses microcystic lymphatic malformations, which affect an estimated 30,000 individuals inside the United States.

There are currently no other FDA-approved therapies available to treat this chronically debilitating vascular condition.